NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

Room: Wren

April 28, 2012 – 9:10 AM – 03:30 PM

Chair: F. Saad

(03:30 PM – 04:30 PM Executive Committee Meeting – Closed)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
- To provide a learning environment supportive to new investigators.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

9:10 am  Welcome and Approval of Previous Minutes  F. Saad

9:15 am  NCIC CTG/INTERGROUP Phase III Trials: Open

PR.13 (RADICALS)/MRC PR.10  C. Catton/F. Saad

9:30 am  NCIC CTG/INTERGROUP Phase III Trials: Closed. Pending Analyses

PR.11  F. Saad
BL 8/EORTC 30994  F. Saad
REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC  J. Knox

9:45 am  Coffee Break

continued on next page ...
10:00 am  **NCIC CTG Phase III Trials: Recent Analyses**

PR.3 – Final analysis  P. Warde/ M. Brundage
PR.8/SWOG 9346  B. Donnelly

10:40 am  **NCIC CTG/Intergroup Phase III Trials: Publications**

BL.7  E. Winquist

10:50 am  **CTSU Trials Activated by NCIC CTG: Open**

PRC.2/CALGB 90202  Early vs. Standard Zoledronic Acid in CaP metastatic to bone  F. Saad
PRC.3/CALGB 90203  Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only  F. Saad

11:10 am  **NCIC CTG IND Trials**

IND.195: A Phase II Study of SB 939 in Patients with CRPC  K. Chi
IND.205: PX-866 in recurrent or metastatic CRPC  S. Hotte
IND.209: Reolysin in combination with docetaxel and prednisone or docetaxel and prednisone alone in metastatic CRPC  K. Chi

11:30 am  **Update on NCIC CTG Approved Studies**

Pilot Study of HDR Brachytherapy in Intermediate Risk CaP  E. Vigneault/ A. Loblaw

11:45 am  **Open CUOG Trials**

12:15 pm  Lunch

1:30 pm  **Update on Closed CUOG Trials**

2:00 pm  **New Study Proposals**

A Phase III Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma  K. Sridhar
Systemic Therapy in Advancing or Metastatic Prostate cancer. STAMPEDE  K. Chi
Abiraterone in CRPC  K. Chi

3:00 pm  **DOG Reports**

Localized Prostate Cancer  A. Loblaw/ N. Fleshner
Advanced Prostate Cancer  K. Chi/ F. Saad
Advanced Bladder  S. North/W. Kassouf
Renal  J. Knox/ A. Kapoor
Testes  C. Kollmaansberger/ P. Chung
Superficial bladder  A. So

3:30 pm  **Meeting Adjourned, Executive Committee Meeting to Follow (Closed)**